Experiencia pediátrica en el tratamiento del asma grave con anticuerpos anti IgE (omalizumab)
Leído
7054
Vecesse ha leído el artículo
3658
Total PDF
3396
Total HTML
Información del artículo
ISSN: 16954033Idioma original: Español
Datos actualizados diariamente
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 16 | 22 | 38 |
| 2025 5 | 50 | 40 | 90 |
| 2025 4 | 47 | 38 | 85 |
| 2025 3 | 29 | 31 | 60 |
| 2025 2 | 56 | 21 | 77 |
| 2025 1 | 26 | 13 | 39 |
| 2024 12 | 25 | 26 | 51 |
| 2024 11 | 29 | 49 | 78 |
| 2024 10 | 30 | 34 | 64 |
| 2024 9 | 37 | 20 | 57 |
| 2024 8 | 43 | 42 | 85 |
| 2024 7 | 33 | 27 | 60 |
| 2024 6 | 25 | 24 | 49 |
| 2024 5 | 42 | 33 | 75 |
| 2024 4 | 35 | 37 | 72 |
| 2024 3 | 23 | 28 | 51 |
| 2024 2 | 26 | 36 | 62 |
| 2024 1 | 21 | 30 | 51 |
| 2023 12 | 19 | 40 | 59 |
| 2023 11 | 29 | 89 | 118 |
| 2023 10 | 25 | 61 | 86 |
| 2023 9 | 24 | 41 | 65 |
| 2023 8 | 21 | 35 | 56 |
| 2023 7 | 22 | 52 | 74 |
| 2023 6 | 27 | 53 | 80 |
| 2023 5 | 38 | 57 | 95 |
| 2023 4 | 16 | 24 | 40 |
| 2023 3 | 20 | 27 | 47 |
| 2023 2 | 15 | 24 | 39 |
| 2022 1 | 22 | 28 | 50 |
| 2022 12 | 33 | 45 | 78 |
| 2022 11 | 32 | 35 | 67 |
| 2022 10 | 27 | 46 | 73 |
| 2022 9 | 25 | 35 | 60 |
| 2022 8 | 26 | 58 | 84 |
| 2022 7 | 23 | 52 | 75 |
| 2022 6 | 17 | 56 | 73 |
| 2022 5 | 30 | 53 | 83 |
| 2022 4 | 19 | 39 | 58 |
| 2022 3 | 30 | 74 | 104 |
| 2022 2 | 20 | 52 | 72 |
| 2021 1 | 23 | 51 | 74 |
| 2021 12 | 14 | 61 | 75 |
| 2021 11 | 28 | 47 | 75 |
| 2021 10 | 28 | 86 | 114 |
| 2021 9 | 20 | 56 | 76 |
| 2021 8 | 18 | 74 | 92 |
| 2021 7 | 27 | 67 | 94 |
| 2021 6 | 27 | 64 | 91 |
| 2021 5 | 24 | 35 | 59 |
| 2021 4 | 49 | 106 | 155 |
| 2021 3 | 17 | 38 | 55 |
| 2021 2 | 12 | 29 | 41 |
| 2020 1 | 18 | 60 | 78 |
| 2020 12 | 23 | 40 | 63 |
| 2020 11 | 38 | 25 | 63 |
| 2020 10 | 50 | 27 | 77 |
| 2020 9 | 37 | 46 | 83 |
| 2020 8 | 26 | 25 | 51 |
| 2020 7 | 39 | 39 | 78 |
| 2020 6 | 33 | 46 | 79 |
| 2020 5 | 35 | 51 | 86 |
| 2020 4 | 21 | 28 | 49 |
| 2020 3 | 24 | 36 | 60 |
| 2020 2 | 30 | 36 | 66 |
| 2020 1 | 16 | 18 | 34 |
| 2019 12 | 17 | 34 | 51 |
| 2019 11 | 21 | 18 | 39 |
| 2019 10 | 17 | 26 | 43 |
| 2019 9 | 33 | 37 | 70 |
| 2019 8 | 24 | 20 | 44 |
| 2019 7 | 35 | 30 | 65 |
| 2019 6 | 18 | 16 | 34 |
| 2019 5 | 22 | 20 | 42 |
| 2019 4 | 23 | 37 | 60 |
| 2019 3 | 21 | 22 | 43 |
| 2019 2 | 14 | 16 | 30 |
| 2019 1 | 17 | 38 | 55 |
| 2018 12 | 30 | 24 | 54 |
| 2018 11 | 30 | 30 | 60 |
| 2018 10 | 42 | 34 | 76 |
| 2018 9 | 10 | 19 | 29 |
| 2018 7 | 2 | 1 | 3 |
| 2018 4 | 9 | 0 | 9 |
| 2018 3 | 11 | 1 | 12 |
| 2018 2 | 7 | 0 | 7 |
| 2018 1 | 10 | 0 | 10 |
| 2017 12 | 11 | 1 | 12 |
| 2017 11 | 10 | 0 | 10 |
| 2017 10 | 14 | 0 | 14 |
| 2017 9 | 7 | 0 | 7 |
| 2017 8 | 10 | 0 | 10 |
| 2017 7 | 19 | 1 | 20 |
| 2017 6 | 20 | 34 | 54 |
| 2017 5 | 28 | 42 | 70 |
| 2017 4 | 22 | 37 | 59 |
| 2017 3 | 17 | 53 | 70 |
| 2017 2 | 8 | 7 | 15 |
| 2016 1 | 10 | 8 | 18 |
| 2016 12 | 7 | 11 | 18 |
| 2016 11 | 13 | 14 | 27 |
| 2016 10 | 23 | 43 | 66 |
| 2016 9 | 20 | 33 | 53 |
| 2016 8 | 31 | 16 | 47 |
| 2016 7 | 18 | 34 | 52 |
| 2015 8 | 1 | 0 | 1 |
| 2015 7 | 1 | 0 | 1 |
| 2015 6 | 3 | 0 | 3 |
| 2015 5 | 2 | 0 | 2 |
| 2015 4 | 5 | 0 | 5 |
| 2015 3 | 1 | 14 | 15 |
| 2015 1 | 2 | 0 | 2 |
| 2014 12 | 6 | 0 | 6 |
| 2014 11 | 5 | 1 | 6 |
| 2014 10 | 9 | 0 | 9 |
| 2014 9 | 7 | 2 | 9 |
| 2014 8 | 7 | 1 | 8 |
| 2014 7 | 11 | 3 | 14 |
| 2014 6 | 11 | 2 | 13 |
| 2014 5 | 10 | 7 | 17 |
| 2014 4 | 11 | 7 | 18 |
| 2014 3 | 11 | 7 | 18 |
| 2014 2 | 12 | 3 | 15 |
| 2014 1 | 13 | 6 | 19 |
| 2013 12 | 12 | 9 | 21 |
| 2013 11 | 25 | 3 | 28 |
| 2013 10 | 18 | 5 | 23 |
| 2013 9 | 10 | 3 | 13 |
| 2013 8 | 18 | 4 | 22 |
| 2013 7 | 11 | 6 | 17 |
| 2010 5 | 643 | 0 | 643 |
Mostrar todo
